secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001274737-25-000055
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen appoints former Silk Road Medical CEO Chas McKhann to Board
------------------------------------------------------------------

- Chas McKhann appointed Class III director effective July 17, 2025; term expiring at 2028 annual meeting.
- Previously served as President/CEO of Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific.
- Board size increased from 7 to 8 members; McKhann also joins Compensation and Nominating Committees.
- McKhann received 7,500 RSUs vesting over 4 years; annual option for 9,000 shares under amended compensation plan.
- Board approved amended non-employee director compensation program effective July 17, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473725000055/0001274737-25-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473725000055/exdx-20250717.htm
  HTML page:      https://secwatch.observer/filing/0001274737-25-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer